Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

Michael O'Riordan

August 24, 2016

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

肺栓塞发作后，二级抗凝效果未持续

L.A. McKeown

July 13, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

Presentation

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Presenter: Francis Couturaud

July 10, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Daily News

HORIZONS-AMI Substudy: Anticoagulation After Primary PCI Yields Worse Outcomes

September 02, 2014

News Daily News

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Yael L. Maxwell

January 01, 2014

News Daily News

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

Yael L. Maxwell

January 01, 2014

News Daily News

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Caitlin E. Cox

April 05, 2013

News Conference News ESC 2012

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Caitlin E. Cox

August 27, 2012

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

Advertisement

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

肺栓塞发作后，二级抗凝效果未持续

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

HORIZONS-AMI Substudy: Anticoagulation After Primary PCI Yields Worse Outcomes

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content